From data to diagnostic: How AI is powering biomarker discovery

Finding a targetable, clinically relevant biomarker has traditionally been slow and expensive: promising signals get lost in noisy, high-dimensional data, and even strong candidates can take years to move from a research finding to an investigational drug. As multimodal datasets grow in scale, AI is becoming essential to finding signal in that complexity and translating it into clinically meaningful biomarkers.

This webinar looks at how Guardant is using AI and machine learning to discover novel multimodal biomarkers, from identifying candidate signals in large multimodal cohorts to training and validating classifiers against real-world patient outcomes. We'll walk through a concrete example: how Guardant used AI and machine learning to discover, validate, and deploy an epigenomic-based lung cancer subtyping feature that noninvasively and accurately predicts lung subtypes from a single blood draw.

We'll also discuss how this advanced lung subtyping feature is being used in clinics today to detect subtype switching and inform smarter, more timely treatment decisions.

Attendees will learn:

How Guardant is using AI and machine learning to discover new biomarkers
A concrete case study: how AI and machine learning was used to discover, validate, and deploy an epigenomic-based lung cancer subtyping feature
How oncologists are using this lung subtyping feature today to make more informed, timely treatment decisions

Amar Das

VP, AI & Translational Medicine

Guardant Health

Dr. Das is the Vice President of AI & Translational Medicine at Guardant Health, Inc., where he leads the global translational analytics mission, vision, and strategy for the organization, creating a connected, comprehensive foundation for data-backed decisions that seamlessly bridges research and operations and transforms data into value. He trained in medicine (MD) and biomedical informatics (PhD) at Stanford University, followed by postdoctoral training in clinical epidemiology at Columbia University, and later served on the faculty at Stanford. Prior to Guardant Health, he also worked at Merck Research Laboratories, IBM Research, and Dartmouth College, where he was the founding director of the Division of Biomedical Informatics.

Ben Herzberg

Medical Oncologist

Columbia University Irving Medical Center

Ben Herzberg is a board-certified medical oncologist at Columbia University Irving Medical Center specializing in thoracic malignancies, including non-small cell and small cell lung cancer, mesothelioma, and thymoma. Dr. Herzberg’s work sits at the intersection of clinical oncology, functional genomics, and drug discovery. As principal investigator and an international steering-committee member for more than 30 clinical trials, he has helped advance therapies directed at RAS, MTAP, SMARCA4, and other synthetic tumor vulnerabilities. His laboratory translates observations from the clinic into strategies for identifying actionable cancer dependencies, deploying targeted therapies more effectively, and reducing treatment-related toxicity. Dr. Herzberg received his undergraduate degree from Princeton University, his MD through the Harvard Medical School–MIT Health Sciences and Technology program, and an MSc in the History of Science and Medicine from Imperial College London. He completed internal medicine training at Massachusetts General Hospital and medical oncology fellowship at Memorial Sloan Kettering Cancer Center, where he served as Chief Fellow.

Justin Odegaard

SVP, Product

Guardant Health

Dr. Odegaard is the Senior Vice President of Product at Guardant Health, Inc., where he has spent the 10 years building, validating, and commercializing cancer molecular diagnostics. He trained in surgical and molecular pathology (MD) and immunology and physiology (PhD) at Stanford University, where he also served on the consulting faculty. Prior to Guardant Health, he also worked at the University of California San Francisco, at OneOme Laboratories, and at Lifecode, Inc.

Country

From data to diagnostic: How AI is powering biomarker discovery

Panelists

Moderator

Register for the webinar